Results 21 to 30 of about 160,832 (337)

Gemcitabine: Progress in the treatment of pancreatic cancer [PDF]

, 2001
Unresectable pancreatic cancer has a dismal prognosis with a median survival of 3-5 months in untreated disease. Since the introduction of gemcitabine, pancreatic cancer may no longer be regarded a chemotherapy-resistant tumor.
Heinemann, Volker
core   +1 more source

Differentiation Therapy Targeting the β-Catenin/CBP Interaction in Pancreatic Cancer. [PDF]

, 2018
BACKGROUND:Although canonical Wnt signaling is known to promote tumorigenesis in pancreatic ductal adenocarcinoma (PDAC), a cancer driven principally by mutant K-Ras, the detailed molecular mechanisms by which the Wnt effector β-catenin regulates such ...
Chen, Yibu, Genyk, Yuri S, Kahn, Michael, Lai, Keane KY, Lenz, Heinz-Josef, Lin, David P, Manegold, Philipp, Nguyen, Cu, Pandol, Stephen J, Teo, Jia-Ling, Wu, Kaijin, Wu, Yongfeng, Zhao, Yi   +12 more
core   +2 more sources

A meta-analysis of gemcitabine containing chemotherapy for locally advanced and metastatic pancreatic adenocarcinoma

Journal of Hematology & Oncology, 2011
Background The objectives of the present study are to investigate the efficacy and safety profile of gemcitabine-based combinations in the treatment of locally advanced and metastatic pancreatic adenocarcinoma (LA/MPC).
Ma Yue, Xu Ying-Chun, Tang Lei, Wang Hong-Xia, Zhao Gang, Hu Jing, Zhang Feng-Chun   +6 more
doaj   +1 more source

Targeting Glycolysis with Epigallocatechin-3-Gallate Enhances the Efficacy of Chemotherapeutics in Pancreatic Cancer Cells and Xenografts. [PDF]

, 2019
Pancreatic cancer is a complex disease, in need of new therapeutic approaches. In this study, we explored the effect and mechanism of action of epigallocatechin-3-gallate (EGCG), a major polyphenol in green tea, alone and in combination with current ...
Hackman, Robert M, Mackenzie, Gerardo G, Wang, Yuefei, Wei, Ran   +3 more
core   +1 more source

Nuclear PLD1 combined with NPM1 induces gemcitabine resistance through tumorigenic IL7R in pancreatic adenocarcinoma

Cancer Biology & Medicine, 2023
Objective: Pancreatic ductal adenocarcinoma (PDAC) is a highly malignant gastrointestinal cancer with a 5-year survival rate of only 9%. Of PDAC patients, 15%-20% are eligible for radical surgery.
Danqi Fu, Jingrui Yan, Zhaoyu Zhang, Yang Liu, Xiaoqing Ma, Jinsheng Ding, Shengyu Yang, Ran Zhao, Antao Chang, Chuntao Gao, Jing Liu, Tiansuo Zhao, Xiuchao Wang, Chongbiao Huang, Song Gao, Ying Ma, Bo Tang, Yukuan Feng, Hongwei Wang, Jihui Hao   +19 more
doaj   +1 more source

Alternative polyadenylation of ZEB1 promotes its translation during genotoxic stress in pancreatic cancer cells [PDF]

, 2017
Pancreatic ductal adenocarcinoma (PDAC) is characterized by extremely poor prognosis. The standard chemotherapeutic drug, gemcitabine, does not offer significant improvements for PDAC management due to the rapid acquisition of drug resistance by patients.
Bielli, Pamela, Capurso, Gabriele, Delle Fave, Gianfranco, Farini, Donatella, Panzeri, Valentina, Passacantilli, Ilaria, Pilozzi, Emanuela, Sette, Claudio   +7 more
core   +2 more sources

Current Oncological Treatment of Patients with Pancreatic Cancer in Germany: Results from a National Survey on behalf of the Arbeitsgemeinschaft Internistische Onkologie and the Chirurgische Arbeitsgemeinschaft Onkologie of the Germany Cancer Society [PDF]

, 2009
Background: No data have previously been available regarding the current treatment of patients with pancreatic cancer (PC) in German hospitals and medical practices.
Boeck, Stefan, Bruns, Christiane J., Heinemann, Volker, Jauch, Karl-Walter, Sargent, Mirja, Schäfer, Claus, Seufferlein, Thomas   +6 more
core   +1 more source

Cancer genomic profiling identified dihydropyrimidine dehydrogenase deficiency in bladder cancer promotes sensitivity to gemcitabine

Scientific Reports, 2022
Chemotherapy is a standard therapy for muscle-invasive bladder cancer (MIBC). However, genomic alterations associated with chemotherapy sensitivity in MIBC have not been fully explored.
Shigehiro Tsukahara, Masaki Shiota, Dai Takamatsu, Shohei Nagakawa, Takashi Matsumoto, Ryo Kiyokoba, Mikako Yagi, Daiki Setoyama, Nozomi Noda, Shinya Matsumoto, Tetsutaro Hayashi, Alberto Contreras-Sanz, Peter C. Black, Junichi Inokuchi, Kenichi Kohashi, Yoshinao Oda, Takeshi Uchiumi, Masatoshi Eto, Dongchon Kang   +18 more
doaj   +1 more source

Gemcitabine and carboplatin in intensively pretreated patients with metastatic breast cancer [PDF]

, 2007
Background: Patients with metastatic breast cancer (MBC) are increasingly exposed to anthracyclines and taxanes either during treatment of primary breast cancer or during initial therapy of metastatic disease.
Fasching, P. A., Heinemann, Volker, Kalischefski, B., Koelbl, H., Laessig, D., Maubach, P., Meerpohl, H., Melchert, F., Morack, G., Scharl, A., Stauch, M., Stemmler, H. J., Vehling-Kaiser, U., Weber, B.   +13 more
core   +1 more source

Src Inhibition Can Synergize with Gemcitabine and Reverse Resistance in Triple Negative Breast Cancer Cells via the AKT/c-Jun Pathway. [PDF]

PLoS ONE, 2016
Gemcitabine-based chemotherapy remains one of the standards in management of metastatic breast cancer. However, intrinsic and acquired resistance to gemcitabine inevitably occurs.
Zhen-Hua Wu, Chen Lin, Ming-Ming Liu, Jian Zhang, Zhong-Hua Tao, Xi-Chun Hu   +5 more
doaj   +1 more source